van Breugel Henrica N A M, Gelsomino Sandro, de Vos Cees B, Accord Ryan E, Tieleman Robert G, Lucà Fabiana, Rostagno Carlo, Renzulli Attilio, Parise Orlando, Lorusso Roberto, Crijns Harry J G M, Maessen Jos G
University Hospital, Maastricht, The Netherlands.
University Hospital, Maastricht, The Netherlands; Careggi Hospital, Florence Italy.
Int J Cardiol. 2014 Aug 1;175(2):290-6. doi: 10.1016/j.ijcard.2014.05.010. Epub 2014 May 16.
This study reports the outcomes of patients who underwent electrical cardioversion for atrial fibrillation recurrence following mitral valve surgery and associated radiofrequency ablation compared to those who did not undergo concomitant atrial fibrillation ablation.
The population consisted of 116 patients with persistent/long-standing persistent AF who underwent mitral valve surgery with (Group A, n=54) or without (Group B, n=62) associated radiofrequency ablation between January 2007 and January 2011 at three institutions and who subsequently underwent cardioversion for persistent atrial fibrillation within 12 months of their initial procedure.
The mean follow-up duration was 30.7±9.4 months. Of the 104 patients with acute restoration of SR 42 (40.3%) had AF recurrence. The average time to recurrence after cardioversion was 7.3±4.2 days. Recurrence was significantly lower in patients undergoing ablation surgery (21.4%) than in those undergoing no ablation surgery (78.6%, p<0.001). Non-performed ablation procedure (p<0.001), time from surgery≥88 days and left atrial dimensions≥45.5 mm before cardioversion (both, p=0.005) were multivariable predictors of atrial fibrillation recurrence. In Group B the use of amiodarone was inversely correlated with recurrence of AF (p<0.001). This correlation was not significant (r=-0.02, p=0.85) in Group A.
Electrical cardioversion for recurrent AF showed better results and stable recovery of sinus rhythm in patients undergoing concomitant surgical ablation during mitral valve surgery. This might be attributable to substrate modification caused by surgical lesions. Amiodarone improved the ECV-success rate only in patients with no associate ablation. Further larger randomized studies are necessary to confirm our findings.
本研究报告了二尖瓣手术后因房颤复发接受电复律并联合射频消融的患者与未接受同期房颤消融患者的治疗结果。
研究对象为2007年1月至2011年1月期间在三家机构接受二尖瓣手术的116例持续性/长期持续性房颤患者,其中54例(A组)接受了联合射频消融,62例(B组)未接受联合射频消融,所有患者在初次手术后12个月内接受了持续性房颤的复律治疗。
平均随访时间为30.7±9.4个月。104例急性恢复窦性心律的患者中,42例(40.3%)出现房颤复发。复律后平均复发时间为7.3±4.2天。接受消融手术的患者复发率(21.4%)显著低于未接受消融手术的患者(78.6%,p<0.001)。未进行消融手术(p<0.001)、手术时间≥88天以及复律前左房内径≥45.5 mm(均为p=0.005)是房颤复发的多变量预测因素。在B组中,胺碘酮的使用与房颤复发呈负相关(p<0.001)。在A组中,这种相关性不显著(r=-0.02,p=0.85)。
对于二尖瓣手术同期接受手术消融的患者,复发性房颤的电复律显示出更好的效果和窦性心律的稳定恢复。这可能归因于手术损伤引起的基质改变。胺碘酮仅在未接受联合消融的患者中提高了电复律成功率。需要进一步开展更大规模的随机研究来证实我们的发现。